% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Meissner:127089,
      author       = {J. Meissner and D. Tichy$^*$ and V. Katzke$^*$ and T.
                      Kühn$^*$ and S. Dietrich and T. Schmitt and M. Ziepert and
                      E. Kuhnt and T. Rixecker and M. Zorn and M. Witzens-Harig
                      and M. Pfreundschuh and A. D. Ho},
      title        = {{L}ong-term ovarian function in women treated with {CHOP}
                      or {CHOP} plus etoposide for aggressive lymphoma.},
      journal      = {Annals of oncology},
      volume       = {26},
      number       = {8},
      issn         = {1569-8041},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-03115},
      pages        = {1771 - 1776},
      year         = {2015},
      abstract     = {Chemotherapy-associated ovarian damage comprises not only
                      infertility, but also premature menopause. The latter has
                      been reported as a consequence of alkylating chemotherapy
                      for breast cancer or Hodgkin's lymphoma. In this study, we
                      assessed the long-term impact of CHOP (cyclophosphamide,
                      doxorubicin, vincristine, and prednisone)-like regimens on
                      ovarian function in patients with aggressive non-Hodgkin
                      lymphoma (NHL).Long-term survivors after CHOP or CHOP plus
                      etoposide (CHOEP) treatment within the Mabthera
                      International Trial or the NHL-B1 trial of the German NHL
                      Study Group were requested to respond to a questionnaire and
                      to consent to blood sampling for hormone assessment.A total
                      of 46 of 81 contacted patients with a median age of 32.5
                      years at the time of enrolment into the aforementioned
                      clinical trials responded to the questionnaire. The median
                      follow-up after completion of treatment was 14 years. Last
                      menstrual bleeding occurred significantly earlier in
                      patients compared with the general population (47 versus 51
                      years, P < 0.0001). In comparison to the distribution of
                      menopausal symptoms in the general population, the
                      percentage of women with moderate or severe menopausal
                      symptoms was increased. In 23 patients who agreed to
                      participate in laboratory analyses, anti-Muller hormone as a
                      marker of ovarian reserve was decreased when compared with
                      correspondent age groups of the general population.Although
                      most female patients regain fertility after CHOP-like
                      chemotherapy, late ovarian impairment occurs frequently.
                      Therefore, awareness of such delayed side-effects at the
                      time of counselling is of importance.},
      keywords     = {Vincristine (NLM Chemicals) / Etoposide (NLM Chemicals) /
                      Doxorubicin (NLM Chemicals) / Anti-Mullerian Hormone (NLM
                      Chemicals) / Cyclophosphamide (NLM Chemicals) / Prednisone
                      (NLM Chemicals)},
      cin          = {C060 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25962442},
      doi          = {10.1093/annonc/mdv227},
      url          = {https://inrepo02.dkfz.de/record/127089},
}